Atorvastatin and Plecebo.docx

This document appears to be a detailed pharmaceutical product specification for an ongoing clinical trial drug supply requirement. The solicitation from the National Institutes of Health (NIH) requires the production of Atorvastatin capsules in two dosage strengths: 20mg (1,050 capsules for 5 patients) and 40mg (4,200 capsules for 20 patients), along with matching placebo capsules (4,200 capsules). The production specifications indicate capsule runs must provide sufficient quantity for patients to take one capsule daily over a 7-month period, with appropriate additional overage to ensure complete study coverage. The solicitation is specifically identified under NIH-SS-7194601-A for an interventional clinical trial study drug procurement, involving the Department of Health and Human Services National Institutes of Health Office of Logistics and Acquisition Operations.